Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

119.63USD
15 Feb 2019
Change (% chg)

$1.09 (+0.92%)
Prev Close
$118.54
Open
$119.05
Day's High
$119.65
Day's Low
$118.38
Volume
103,196
Avg. Vol
148,463
52-wk High
$139.24
52-wk Low
$100.29

Latest Key Developments (Source: Significant Developments)

Health Canada Approves Unituxin For Treatment Of Pediatric High-Risk Neuroblastoma
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - United Therapeutics Corp ::HEALTH CANADA APPROVES UNITUXIN® FOR THE TREATMENT OF PEDIATRIC HIGH-RISK NEUROBLASTOMA.UNITED THERAPEUTICS CORP - SAFETY INFORMATION FOR UNITUXIN CONTAINS BOXED WARNING ABOUT SERIOUS INFUSION REACTIONS.  Full Article

United Therapeutics Corp Reports Q3 2018 Results
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - United Therapeutics Corp ::ORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.QTRLY EARNINGS PER SHARE $2.42.QTRLY ADJUSTED EARNINGS PER SHARE $3.98.QTRLY REVENUES $412.7 MILLION VERSUS $445.5 MILLION.Q3 EARNINGS PER SHARE VIEW $3.25, REVENUE VIEW $380.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

CollPlant And United Therapeutics Announce Global Licensing And Commercialization Agreement
Monday, 22 Oct 2018 

Oct 22 (Reuters) - United Therapeutics Corp ::COLLPLANT AND UNITED THERAPEUTICS ANNOUNCE GLOBAL LICENSING AND COMMERCIALIZATION AGREEMENT FOR 3D BIOPRINTING OF SOLID-ORGAN SCAFFOLDS FOR HUMAN TRANSPLANTS.COLLPLANT WILL RECEIVE AN UPFRONT PAYMENT OF $5 MILLION.COLLPLANT WILL RECEIVE MILESTONE PAYMENTS OF UP TO $15 MILLION.COLLPLANT ENTITLED TO GET ROYALTIES ON SALES OF COMMERCIALIZED PRODUCTS COVERED BY PATENTS LICENSED FROM IT.COLLPLANT WILL MANUFACTURE AND SUPPLY BIOINK FOR A FEW YEARS TO MEET DEVELOPMENT PROCESS DEMAND.COLLPLANT TO GIVE TECHNICAL SUPPORT TO CO AS IT ESTABLISHES U.S. FACILITY FOR MANUFACTURE OF COLLPLANT'S RHCOLLAGEN, BIOINK.  Full Article

United Therapeutics And Mannkind Announce Collaboration For Pulmonary Hypertension Products
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - MannKind Corp ::UNITED THERAPEUTICS AND MANNKIND ANNOUNCE COLLABORATION FOR PULMONARY HYPERTENSION PRODUCTS.MANNKIND CORP - MANNKIND CORPORATION WILL RECEIVE AN UPFRONT PAYMENT OF $45 MILLION.MANNKIND CORP - MANNKIND WILL ALSO RECEIVE POTENTIAL MILESTONE PAYMENTS OF UP TO $50 MILLION.MANNKIND CORP - WILL BE ENTITLED TO RECEIVE LOW DOUBLE-DIGIT ROYALTIES ON NET SALES OF PRODUCT.MANNKIND - GRANTED UNITED THERAPEUTICS AN OPTION TO EXPAND LICENSE TO INCLUDE OTHER ACTIVE INGREDIENTS FOR TREATMENT OF PULMONARY HYPERTENSION.  Full Article

United Therapeutics And Mannkind Announce Collaboration For Pulmonary Hypertension Products
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - MannKind Corp ::UNITED THERAPEUTICS AND MANNKIND ANNOUNCE COLLABORATION FOR PULMONARY HYPERTENSION PRODUCTS.UNITED THERAPEUTICS CORP - EXCLUSIVE LICENSE AGREEMENT FOR TREPROSTINIL TECHNOSPHERE.UNITED THERAPEUTICS CORP - $95 MILLION IN UPFRONT AND MILESTONE PAYMENTS UNDER DEAL.UNITED THERAPEUTICS CORP - RESEARCH AGREEMENT FOR ADDITIONAL PRODUCTS FOR ADDITIONAL $10 MILLION.  Full Article

United Therapeutics Announces Freedom-Ev Study Of Orenitram Meets Primary Endpoint
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS ANNOUNCES FREEDOM-EV STUDY OF ORENITRAM MEETS PRIMARY ENDPOINT.UNITED THERAPEUTICS CORP - STUDY MET ITS PRIMARY ENDPOINT OF DELAYED TIME TO FIRST CLINICAL WORSENING EVENT.UNITED THERAPEUTICS CORP - ANALYSIS OF SECONDARY ENDPOINTS IS ONGOING.UNITED THERAPEUTICS - PLANS TO SUBMIT RESULTS TO U.S. FDA IN SUPPORT OF LABEL AMENDMENT TO REFLECT FREEDOM-EV RESULTS.UNITED THERAPEUTICS - EVALUATING IF RESULTS COULD SUPPORT MARKETING APPLICATIONS FOR ORENITRAM OUTSIDE U.S..  Full Article

United Therapeutics Corp Reports Qtrly Earnings Per Share $3.98
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - United Therapeutics Corp ::ORATION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $444 MILLION VERSUS I/B/E/S VIEW $368.6 MILLION.UNITED THERAPEUTICS - QTRLY NON-GAAP EARNINGS PER SHARE $4.36.UNITED THERAPEUTICS - QTRLY EARNINGS PER SHARE $3.98.Q2 EARNINGS PER SHARE VIEW $3.16 -- THOMSON REUTERS I/B/E/S.  Full Article

United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®
Tuesday, 31 Jul 2018 

July 31 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS ANNOUNCES FDA APPROVAL OF THE IMPLANTABLE SYSTEM FOR REMODULIN®.UNITED THERAPEUTICS - APPROVAL OF NDA FOR USE OF REMODULIN INJECTION IN IMPLANTABLE SYSTEM FOR REMODULIN.  Full Article

United Therapeutics Corp Says Co Entered Into A Credit Agreement
Thursday, 28 Jun 2018 

June 28 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS CORP SAYS ON JUNE 27, ENTERED INTO A CREDIT AGREEMENT - SEC FILING.UNITED THERAPEUTICS CORP - CREDIT AGREEMENT PROVIDES FOR AN UNSECURED REVOLVING CREDIT FACILITY OF UP TO $1.0 BILLION.UNITED THERAPEUTICS CORP - CREDIT AGREEMENT ALSO PROVIDES FOR A SECOND UNSECURED REVOLVING CREDIT FACILITY OF UP TO $500 MILLION.UNITED THERAPEUTICS CORP - FACILITIES MATURE FIVE YEARS AFTER CLOSING DATE OF CREDIT AGREEMENT.UNITED THERAPEUTICS CORP - PROCEEDS OF BORROWINGS UNDER CREDIT AGREEMENT ARE AVAILABLE TO REFINANCE CERTAIN EXISTING INDEBTEDNESS OF COMPANY.UNITED THERAPEUTICS CORP - UPON CLOSING OF CREDIT AGREEMENT ON JUNE 27, 2018, BORROWED $250.0 MILLION UNDER CREDIT AGREEMENT.  Full Article

United Therapeutics To Acquire SteadyMed Ltd
Monday, 30 Apr 2018 

April 30 (Reuters) - SteadyMed Ltd ::UNITED THERAPEUTICS TO ACQUIRE STEADYMED LTD..UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION.STEADYMED LTD - UNITED THERAPEUTICS WILL ACQUIRE STEADYMED FOR $4.46 PER SHARE IN CASH AT CLOSING.UNITED THERAPEUTICS-WILL ALSO PAY AN ADDITIONAL $2.63 PER SHARE IN CASH UPON A MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT.STEADYMED LTD - STEADYMED SHAREHOLDERS OWNING ABOUT 43.3 PERCENT OF STEADYMED ORDINARY SHARES ENTERED AGREEMENT TO VOTE THEIR SHARES IN FAVOR OF DEAL.  Full Article

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.